 FOSTER CITY, Calif.--BUSINESS WIRE--Geron Corporation Nasdaq: GERN, a late-stage clinical biopharmaceutical company, today announced that two poster presentations of new clinical data and analyses related to imetelstat, the Companys first-in-class telomerase inhibitor, will be made at the European Hematology Association EHA Annual Congress meeting to be held virtually from June 9 - 17. The abstracts for the posters are available on the EHA website at Both posters will be 